Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Biochemical aspects of migraine pathogenesis
https://doi.org/10.33667/2078-5631-2023-33-34-36
Abstract
The article provides an analysis of modern literature sources devoted to the biochemical aspects of the pathogenesis of migraine. The role of the trigeminovascular system, etc. is described. biologically active substances involved in this process. Understanding the described processes makes it possible to increase the duration and quality of life of patients.
About the Authors
Yu. V. Boldyreva
Tyumen State Medical University
Russian Federation
Russian Federation
Boldyreva Yulia V., PhD Med, associate professor, associate professor at Dept of Biological Chemistry of the Institute of Pharmac
Tyumen
I. A. Lebedev
Tyumen State Medical University
Russian Federation
Russian Federation
Lebedev Ilya A., DM Sci (habil.), professor at Dept of Topographic Anatomy of the Institute of Clinical Medicine
Tyumen
S. N. Suplotov
Tyumen State Medical University
Russian Federation
Russian Federation
Suplotov Sergey N., DM Sci (habil.), professor, head of Dept of Clinical Laboratory Diagnostics of the Institute of Clinical Medicine
Tyumen
M. V. Bazhina
Tyumen State Medical University
Russian Federation
Russian Federation
Bazhina Maria V., first-year resident
Tyumen
E. A. Gavrilenko
Tyumen State Medical University
Russian Federation
Russian Federation
Gavrilenko Elena A., 4th year student of the Institute of Motherhood and Childhood
Tyumen
O. V. Senatorov
Tyumen State Medical University
Russian Federation
Russian Federation
Senatorova Olga V., PhD Med, associate professor at Dept of Childhood Diseases with a course in outpatient pediatrics at the Institute of Motherhood and Childhood
Tyumen
References
1. Ashina M., Migraine N., Engl J. Med. 2020 Nov 5; 383 (19): 1866–1876. https://doi.org/10.1056/nejmra1915327. PMID: 33211930.
2. Moskowitz M. A. The neurobiology of vascular head pain. Ann Neurol 16 (2): 157–168. https://doi.org/10.1002/ana.410160202
3. Ashina M., Hansen J. M., Do T. P., Melo-Carrillo A., Burstein R., Moskowitz M. A. Migraine and the trigeminovascular system – 40 years and counting. Lancet Neurol 18 (8): 795–804. https://doi.org/10.1016/s1474–4422(19)30185–1
4. Ashina M., Terwindt G. M., Al-Karagholi MA-M et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397 (10283): 1496–1504. https://doi.org/10.1016/S0140–6736(20)32162–0
5. Del Fiacco M., Quartu M., Boi M., Serra M. P., Melis T., Boccaletti R. et al. TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. J Neurol Neurosurg Psychiatry. (2015) 86: 393–7. DOI: 10.1136/jnnp‑2014–308813.
6. Su M., Yu S. Chronic migraine: A process of dysmodulation and sensitization. Mol Pain. (2018) 14: 1–10. DOI: 10.1177/1744806918767697.
7. Agostoni E. C., Barbanti P., Calabresi P., Colombo B., Cortelli P., Frediani F. et al. Current and emerging evidence-based treatment options in chronic migraine: A narrative review. J Headache Pain. (2019) 20: 1–9. DOI: 10.1186/s10194–019–1038–4.
8. Cernuda-Morollón E., Martínez-Camblor P., Ramón C., Larrosa D., Serrano-Pertierra E., Pascual J. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. (2014) 54: 987–95. DOI: 10.1111/head.12372.
9. Shimizu T., Shibata M., Toriumi H., Iwashita T., Funakubo M., Sato H. et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis. (2012) 48: 367–78. DOI: 10.1016/j.nbd.2012.07.010.
10. Kondratyeva N. S. Characteristics of molecular genetic markers of migraine pathogenesis. Dissertation for the degree of candidate of biological sciences in the specialty. 2016. T. 3.
11. Cernuda-Morollón E., Larrosa D., Ramón C., Vega J., Martínez-Camblor P., Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. (2013) 81: 1191–6. DOI: 10.1212/wnl.0b013e3182a6cb72.
12. Cernuda-Morollón E., Martínez-Camblor P., Alvarez R., Larrosa D., Ramón C., Pascual J. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. (2015) 35: 310–6. DOI: 10.1177/0333102414535111.
13. Filippi M., Messina R. The chronic migraine brain: What have we learned from neuroimaging? Front Neurol. (2019) 10: 1–10. DOI: 10.3389/fneur.2019.01356.
14. Pérez-Pereda S., Toriello-Suárez M., Ocejo-Vinyals G., Guiral-Foz S., Castillo-Obeso J., Montes-Gómez S. et al. Serum CGRP, VIP, and PACAP usefulness in migraine: A case-control study in chronic migraine patients in real clinical practice. Mol Biol Rep. (2020) 47: 7125–38. DOI: 10.1007/s11033–020–05781–0.
15. Edvinsson L., Juul R., Jansen I. Perivascular neuropeptides (NPY, VIP, CGRP and SP) in human brain vessels after subarachnoid haemorrhage. Acta Neurol Scand. (1994) 90: 324–30. DOI: 10.1111/j.1600–0404.1994.tb02732.x.
16. Hirabayashi T., Nakamachi T., Shioda S. Discovery of PACAP and its receptors in the brain. J Headache Pain. (2018) 19: 1–8. DOI: 10.1186/s10194–018–0855–1.
17. Ghatei M. A., Takahashi K., Suzuki Y., Gardiner J., Jones P. M., Bloom S. R. Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol. (1993) 136: 159–66. DOI: 10.1677/joe.0.1360159.
18. Amin F. M., Hougaard A., Schytz H. W., Asghar M. S., Lundholm E., Parvaiz A. I. et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide‑38. Brain. (2014) 137: 779–94. DOI: 10.1093/brain/awt369.
19. Rahmann A., Wienecke T., Hansen J. M., Fahrenkrug J., Olesen J., Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. (2008) 28: 226–36. DOI: 10.1111/j.1468–2982.2007.01497.x.
20. Hansen J. M., Sitarz J., Birk S., Rahmann A. M., Oturai P. S., Fahrenkrug J. et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. (2006) 26: 992–1003. DOI: 10.1111/j.1468–2982.2006.01149.x.
21. Markovics A., Kormos V., Gaszner B., Lashgarara A., Szoke E., Sandor K. et al. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol- induced trigeminovascular activation in mice. Neurobiol Dis. (2012) 45: 633–44. DOI: 10.1016/j.nbd.2011.10.010.
22. Ploug K. B., Baun M., Hay-Schmidt A., Olesen J., Jansen-Olesen I. Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur J Pharmacol. (2010) 637: 109–17. DOI: 10.1016/j.ejphar.2010.03.027.
23. Ploug K. B., Amrutkar D. V., Baun M., Ramachandran R., Iversen A., Lund T. M. et al. K (ATP) channel openers in the trigeminovascular system. Cephalalgia. (2012) 32: 55–65. DOI: 10.1177/0333102411430266.
24. Al-Karagholi M.A., Ghanizada H., Hansen J. M., Skovgaard L. T., Olesen J., Larsson H. B.W. et al. Levcromakalim, an adenosine triphosphate-sensitive potassium channel opener, dilates extracerebral but not cerebral arteries. Headache. (2019) 59: 1468–80. DOI: 10.1111/head.13634.
25. Al-Karagholi M.A., Ghanizada H., Nielsen C. W., Hougaard A., Ashina M. Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain. (2021). DOI: 10.1093/brain/awab136. [Epub ahead of print]
26. Al-Karagholi M.A., Hansen J. M., Guo S., Olesen J., Ashina M. Opening of ATP-sensitive potassium channels causes migraine attacks: A new target for the treatment of migraine. Brain. (2019) 142: 2644–54. DOI: 10.1093/brain/awz199.
27. Young N. P., Philpot L. M., Vierkant R. A., Rosedahl J. K., Upadhyaya S. G., Harris A. et al. Episodic and chronic migraine in primary care. Headache. (2019) 59: 1042–51. DOI: 10.1111/head.13543.
28. Diener H. C., Dodick D. W., Goadsby P. J., Lipton R. B., Olesen J., Silberstein S. D. Chronic migraine–classification, characteristics and treatment. Nat Rev Neurol. (2012) 8: 162–71. DOI: 10.1038/nrneurol.2012.13.
29. Kukushkin M. L. What causes migraine pain? Russian Journal of Pain. 2018 (3): 87–95. https://doi.org.10.25731/rasp.2018.03.023.
30. Xu H., Han W., Wang J., Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. The Journal of Headache and Pain 2016; 17: 113–131.
Review
For citations:
Boldyreva Yu.V., Lebedev I.A., Suplotov S.N., Bazhina M.V., Gavrilenko E.A., Senatorov O.V. Biochemical aspects of migraine pathogenesis. Medical alphabet. 2023;(33):34-36. (In Russ.) https://doi.org/10.33667/2078-5631-2023-33-34-36
Views:
493
Email this article 